Wednesday, May 8, 2019
Dyadic International (DYAI)
What Does Another Licensing Agreement Mean?
Dyadic International Inc. is a biotechnology company developing a proprietary C1 expression platform to express and manufacture biologic products. The C1 technology is part of a fungi expression system, which utilizes inexpensive substrates yielding a high level of production. Dyadic is currently improving and optimizing the production of biological products in a C1 expression system.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Second Sub-licensing Deal. Following a sub-licensing deal with Luina Bio announced on April 29, the company announced a second sub-licensing agreement with biotech company Alphazyme. Alphazyme produces molecular biology enzymes for the molecular tool industry including, custom DNA and RNA molecules, genomic medicines and genetic testing. Dyadic’s C1 technology platform meets Alphazyme’s requirements for high quality, low cost production of enzymes on an industrial scale.
- Terms of the Deal. Dyadic will be granted an equity stake in Alphazyme,
and is entitled to receive milestone payments and royalties upon the
commercialization of C1 expressed Alphaz…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.
